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Introduction
Infantile hemangiomas are the most common infantile tumor [1, 2] .
The prevalence of Infantile hemangioma in mature neonates is around 4.5% with a female (2.3-2.9 times higher) and white predominance [3] . The predominant locations are head and neck [4] . They arise in initial few weeks of life and then display a period of active growth followed by spontaneous involution. The proliferative phase spreads over three to six months. Most Infantile hemangiomas do not require therapy and regress spontaneously over months to years. However, about 10-15% of the cases result in complications such as obstruction, ulceration and disfigurement. It may also carry risk of bleeding. Treatment is required in such conditions [1] . Therapeutic effect of Propranolol over Infantile hemangioma was detected incidentally in the year 2008, when regression of facial hemangioma was noted in a child while being treated for hypertrophic cardiomyopathy by this molecule [5] . Since then, it is being used for infantile hemangioma and currently oral Propranolol is the treatment of choice for this condition [6] .
However, there is lack of consensus over its dosage as cited in literature of different studies [7] [8] [9] .
Propranolol has been used for cardiovascular indications in the dosage up to 4mg/kg/d, but for treatment of infantile hemangioma, a lower dose is required. For treatment of Infantile hemangioma, some studies favor a lower dose (1-1.5 mg/kg/dose) [7, 8] , while others favor a higher dose (3mg/kg/day) [9] . The precise mechanism of action of Propranolol in the treatment of infantile hemangioma is unclear. The possible mechanisms include vasoconstriction, inhibition of angiogenesis and induction of apoptosis [6] . Although Propranolol has been widely used for this indication, other Beta blockers like Nadolol [10] [11] [12] [13] and Acebutolol [14] have also been shown to be effective for Infantile hemangioma in small non-controlled studies. Other agents with reported activity in treating Infantile hemangioma include corticosteroids, Interferon alpha and Vinca alkaloids [15] . Besides pharmacotherapy, other treatment modalities include Laser therapy and surgical resection.
Sometimes a combination of these modalities is required [16] . We conducted a prospective cross sectional study in 25 cases of infantile hemangioma to find out appropriate dosage of oral Propranolol for treatment of this condition.
Methods
Twenty seven patients of age 2 months and older, with vascular lesions suggestive of infantile hemangioma on clinical grounds, were selected. Approval from ethics committee of the institute was taken.
History of any hypoglycemic event with the child was enquired.
History of any heart block in the mother was also enquired in view of its potential association with complete heart block in the child.
Baseline heart rate & blood pressure were noted. ECG and echocardiography were done to rule out any conduction or structural abnormality. Ultrasonography of the vascular lesions was done to confirm the diagnosis of infantile hemangioma. For this study, response was defined as 'subsided' when there was ≥ 90% reduction in size of tumor and 'partial' when reduction in tumor size was < 90%. Lei chang et al. used the similar parameter of measurement for labeling hemangioma as 'regression' and 'partial regression' after propranolol therapy [17] . In non-responders, the dose of propranolol was gradually increased at the rate of 0.5mg/kg/d every month till any response was observed or the maximum dose of 3-4mg/kg/dose was achieved. If no response was noted, one month after the maximum dose, propranolol was discontinued in them. In responder group, the criteria for tapering off propranolol was decided on the basis of subsidence of the tumor, decrease in tumor size and keeping the same size for 3 consecutive months and the child has received a minimum of 6 months of therapy. Follow up was done for 6 months after completion of therapy.
Results

patients were started on oral Propranolol for treatment of their
Infantile hemangioma. There were 18 males and 7 females (Table   1 ). Head and neck region was predominantly involved (76%) with infantile hemangioma (Figure 1 (Table 3 ). Follow up was done for 6 months after completion of therapy. 2/21 (10%) patients showed recurrence of lesion after completion of therapy. They were 10 months and 11 months old after completion of 6 months and 9 months of therapy respectively. They responded with further extending the duration of therapy for 6 months after restarting with the previous dose of 1.5 mg/kg/day.
Discussion
After the incidental discovery of therapeutic effect of oral propranolol in treatment of infantile hemangioma, it has become the treatment of choice [18] . Most of the superficial hemangioma responded to the lower dose of propranolol (1.5mg/kg/dose) and those who responded, showed response within one week of starting treatment. Maximum response was noted in infants (< 1 year age group). Ren W et al (2017) also described effectiveness of low dose propranolol (1-1.5mg/kg/day) with change in color and growth of the tumor within one week [7] . Gabor Katona et al (2012) described resembling findings of the effect of propranolol used in the dosage of 2mg/kg/day, as regression in tumor size in first week [19] . After initial regression, the later improvement is much slower, sometimes with periods of stagnation. The treatment should be continued for at least 6 months because early cessation can cause a relapse [19] .
Cessation of therapy before 1 year of age also may be associated with a relapse [20, 21] .
Page number not for citation purposes 4 Ultrasonography is a good tool for objective assessment of the change in tumor size [22] . Leaute-Labreze et al.conducted a controlled trial with 1mg/kg/d and 3 mg/kg/d of oral propranolol with approximately 100 patient in each group. They found complete or near complete resolution of the hemangioma after six months of oral propranolol in 50% of the patients in 1 mg/kg/d group as compared to 60% in 3 mg/kg/day group, but the side effects like hypotension was more common in 3mg/kg group (3% vs 1%).
Similarly Bronchospasm was more common in 3 mg/kg group compared to 1 mg/kg group (1% vs 0%) [23] . They observed that agitation as a side effect is more common in 1 mg/kg group (18%) as compared to 3 mg/kg(8%) group. This means that this side effect of propranolol is dose independent. We also observed irritability in 8% of children after starting propranolol therapy. This is important to explain to the caregiver of the child regarding possible side effects of propranolol before starting treatment. Lei Chang et al. described that there is individual variation of response after administration of propranolol. Chinese subjects have at least two fold greater sensitivity to propranolol [17] . We also suggest that 4mg/kg/day), it is unlikely that infantile hemangioma will respond to this pharmacotherapy and it should be discontinued to consider other modalities of treatment. Most of the patients can be managed as outpatient. Parents should be explained regarding possible side effects of propranolol including hypoglycemia and should be advised that the child needs to be fed regularly. They should also be explained that in case of any adverse event, they should discontinue propranolol and take medical consultation in nearby health facility.
Inpatient management has been advocated for infants and children with -corrected gestational age of ≤ 8weeks, inadequate social support, comorbid conditions affecting the cardiovascular system, symptomatic airway hemangioma and history of hypoglycemia. As recurrence is more common if propranolol is stopped before 6 months of treatment or before 1 year of age of the child, it is logical to use lower dose for a longer period rather than higher dose for a shorter period.
Conclusion
Oral propranolol in the lower dose of 1-1.5 mg/kg/day is safe and Other modalities of therapy should be considered in them.
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